Number of Patients, Male	14
Number of Patients, Female	18
Stage	Metastatic, 30; locally advanced, 2
Age	Median (range): 62 (34–81) years
Number of Prior Systemic Therapies	Median: null
Performance Status: ECOG	0 — 15 1 — 17 2 — 0 3 — 0 Unknown — 0
Other	We enrolled 46 patients with advanced solid tumors at 12 sites in the U.S. between February 23, 2017, and March 8, 2019. Forty‐five patients were treated with SGN‐2FF (32 patients in part A, 6 patients in part B, and 7 patients in part C; Fig. 3). The median duration of treatment in part A was 9.1 weeks (range, 0–57). The majority of patients in part A were White (75%) and female (56%); 27% of patients had received prior therapy with checkpoint inhibitors. Patient characteristics for the 32 treated patients in part A are displayed in Table 1.
Cancer Types or Histologic Subtypes	Breast carcinoma, 13 Colorectal carcinoma, 8 Non‐small cell lung cancer, 7 Squamous cell carcinoma of head and neck, 2 Urothelial carcinoma, 2 Gastric/gastroesophageal adenocarcinoma, 0